The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–15.

Article  CAS  PubMed  Google Scholar 

Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2021;84(1):46–52.

Article  PubMed  Google Scholar 

Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–6.

Article  PubMed  Google Scholar 

Liu J, Thatiparthi A, Martin A, Egeberg A, Wu JJ. Prevalence of psoriasis among adults in the US 2009–2010 and 2013–2014 National Health and Nutrition Examination Surveys. J Am Acad Dermatol. 2021;84(3):767–9.

Article  PubMed  Google Scholar 

Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863–72.

Article  CAS  PubMed  Google Scholar 

Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.

Article  PubMed  PubMed Central  Google Scholar 

Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149(10):1173–9.

Article  PubMed  PubMed Central  Google Scholar 

Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-92.e4.

Article  PubMed  Google Scholar 

Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54-e.

Article  Google Scholar 

Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–11.

Article  CAS  PubMed  Google Scholar 

Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Assan F, Tubach F, Arlegui H, et al. First-line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort PSOBIOTEQ. Dermatology. 2021;237(3):338–46.

Article  CAS  PubMed  Google Scholar 

Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76.

Article  CAS  PubMed  Google Scholar 

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72.

Article  PubMed  Google Scholar 

FDA [Internet]. Food and Drug Administration. TREMFYA (guselkumab) Injection. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf. Accessed 20 Mar 2022.

Armstrong AW, Fitzgerald T, McLean RR, et al. Effectiveness of guselkumab therapy among patients with plaque psoriasis with baseline IGA score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022;13:487–504.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong AW, Fitzgerald T, McLean RR, et al. Real-world effectiveness of 9–12 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022;13:629–40.

Article  PubMed  PubMed Central  Google Scholar 

Chan Y, Tong BSB, Ngan PY, Au CS. Effectiveness of IL-23 inhibitor guselkumab in real-world Chinese patients with psoriasis during a 20-week period. Psoriasis (Auckl). 2021;11:53–8.

PubMed  Google Scholar 

del Alcázar E, López-Ferrer A, Martínez-Doménech Á, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022;35(2): e15231.

PubMed  Google Scholar 

Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gerdes S, Bräu B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854–62.

Article  CAS  PubMed  Google Scholar 

Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205–12.

CAS  PubMed  Google Scholar 

Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560–4.

Article  CAS  PubMed  Google Scholar 

Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6): e13964.

Article  CAS  PubMed  Google Scholar 

Zhuang J-Y, Li J-S, Zhong Y-Q, et al. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population. Dermatol Ther. 2021;34(5): e15054.

Article  CAS  PubMed  Google Scholar 

Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018;178(1):132–9.

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Armstrong AW, Langley RG et al. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. J Dermatolog Treat. 2022;33(4):2317–24.

Article  CAS  PubMed  Google Scholar 

Wang Y, Beydoun MA, Min J, Xue H, Kaminsky LA, Cheskin LJ. Has the prevalence of overweight, obesity and central obesity levelled off in the United States? Trends, patterns, disparities, and future projections for the obesity epidemic. Int J Epidemiol. 2020;49(3):810–23.

Article  PubMed  PubMed Central  Google Scholar 

Williamson K, Nimegeer A, Lean M. Rising prevalence of BMI ≥40 kg/m^2: a high-demand epidemic needing better documentation. Obes Rev. 2020;21(4): e12986.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Noncommunicable diseases country profiles 2018. 2018.

Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–32.

Article  PubMed  Google Scholar 

Strober BE, Germino R, Guana A, et al. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. J Dermatolog Treat. 2020;31(4):333–41.

Article  CAS  PubMed  Google Scholar 

Walsh JA, Callis Duffin K, Van Voorhees AS, et al. Demographics, disease characteristics, and patient-reported outcomes among patients with psoriasis who initiated guselkumab in CorEvitas’ Psoriasis Registry. Dermatol Ther (Heidelb). 2022;12(1):97–119.

Article  PubMed  Google Scholar 

Bożek A, Reich A. The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 2017;26(5):851–6.

Article  PubMed  Google Scholar 

EuroQoL Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.

Article  Google Scholar 

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

Article  CAS  PubMed  Google Scholar 

Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23–31.

Article  CAS  PubMed  Google Scholar 

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.

Article  CAS  PubMed  Google Scholar 

Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4): e027535.

Article  PubMed  PubMed Central 

留言 (0)

沒有登入
gif